One more error to avoid
August 1, 2000
One more error to avoid
Serious adverse events have occurred recently from dispensing errors involving Lamictal (lamotrigine) and Lamisil (terbinafine) tablets, according to MedWatch Report. The antiepileptic agent Lamictal has been dispensed when the antifungal Lamisil was prescribed, and vice versa.
Glaxo Wellcome, manufacturer of Lamictal, issued a letter to pharmacists dated June 6, 2000, reporting the errors and asking that pharmacists be alert for prescriptions of both drugs. Proper measures to avoid errors should be assessed and implemented as appropriate. Any dispensing errors should be reported to Glaxo Wellcome, (800) 334-4135, for Lamictal; Novartis Pharmaceuticals, (888) 669-6682, for Lamisil; the USP Medication Errors Reporting Program, (800) 233-7767; or the FDA MedWatch Program, (800) FDA-1088.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content